Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CDC7 | O00311 | 1/20 | 0.34 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 4/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 3/20 | 0.33 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.33 |
| ▸ | FNTA | P49354 | 1/20 | 0.32 |
| ▸ | FNTB | P49356 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9315885 | 0.88 | KMT2A (0.38) | KMT2AMEN1ALDH1A1CDC7DBF4 | |
| SCHEMBL6489633 | 0.81 | KMT2A (0.39) | KMT2AMEN1ALDH1A1CDC7DBF4 | |
| SCHEMBL11680189 | 0.67 | SMN1; SMN2 (0.46) | KMT2AMEN1ALDH1A1CDC7DBF4 | |
| SCHEMBL9315853 | 0.66 | ACHE (0.37) | KMT2AMEN1ALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL10305066 | 0.66 | TDP1 (0.46) | KMT2AMEN1ALDH1A1TDP1RAB9A | |
| SCHEMBL9316395 | 0.65 | ALDH1A1 (0.35) | ALDH1A1TRPM8 | |
| SCHEMBL2490236 | 0.65 | KMT2A (0.47) | KMT2AMEN1ALDH1A1CDC7DBF4 | |
| SCHEMBL20702561 | 0.65 | CTDSP1 (0.54) | KMT2AMEN1ALDH1A1CDC7DBF4 | |
| Ethyl Propionate SCHEMBL29088282 | 0.65 | CDC7 (0.41) | KMT2AMEN1ALDH1A1CDC7DBF4 | |
| SCHEMBL28148509 | 0.64 | HSP90AA1 (0.33) | ALDH1A1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831199-B1 | MMP inhibitors | ASTRAZENECA AB (SE) | 2012-02-15 | — | — | EP | disclosed |
| US-20100256166-A1 | Novel Hydantoin Derivatives as Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2010-10-07 | — | — | US | disclosed |
| US-7700604-B2 | Hydantoin derivatives as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2010-04-20 | — | — | US | disclosed |
| US-7655664-B2 | Hydantoin derivatives as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2010-02-02 | — | — | US | disclosed |
| US-20080293743-A1 | Novel Hydantoin Derivatives as Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| US-20080032997-A1 | Novel Hydantoin Derivatives as Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-02-07 | — | — | US | disclosed |
| EP-1831196-A1 | NOVEL HYDANTOIN DERIVATIVES AS METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006065216-A1 | NOVEL HYDANTOIN DERIVATIVES AS METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
| US-6951863-B2 | Pyridoarylphenly oxazolidinone antibacterials, and related compositions and methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-10-04 | — | — | US | disclosed |
| EP-1358185-A2 | PYRIDOARYLPHENYL OXAZOLIDINONE ANTIBACTERIALS, AND RELATED COMPOSITIONS AND METHODS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2003-11-05 | — | — | EP | disclosed |
| US-20030176422-A1 | For therapy of bacterial infections in humans and animals | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-09-18 | — | — | US | disclosed |
| WO-2002064574-A2 | PYRIDOARYLPHENYL OXAZOLIDINONE ANTIBACTERIALS, AND RELATED COMPOSITIONS AND METHODS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256166-A1 | Novel Hydantoin Derivatives as Metalloproteinase Inhibitors | MMP1, MMP2, MMP9 | KMT2A 786/4885MEN1 1095/4885ALDH1A1 169/4885 |
| US-20080032997-A1 | Novel Hydantoin Derivatives as Metalloproteinase Inhibitors | MMP1, MMP2, MMP9 | KMT2A 786/4885MEN1 1095/4885ALDH1A1 169/4885 |
| US-20030176422-A1 | For therapy of bacterial infections in humans and animals | OXA1L, PIGS, NDUFS3 | KMT2A 4609/4885MEN1 3703/4885ALDH1A1 916/4885 |
| US-20080293743-A1 | Novel Hydantoin Derivatives as Metalloproteinase Inhibitors | MMP1, MMP2, MMP9 | KMT2A 786/4885MEN1 1095/4885ALDH1A1 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.